{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:06Z","timestamp":1791335646049,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pleural mesothelioma (PM) is an aggressive cancer with poor prognosis, often driven by asbestos exposure. Mutations in the <jats:italic>NF2<\/jats:italic> gene, a key regulator of the Hippo signaling pathway, are frequently observed in PM. However, their impact on tumor biology, immune infiltration, cytokine signaling, and therapeutic response remains poorly understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using data from The Cancer Genome Atlas, we analyzed 82 PM cases to assess the prevalence and consequences of <jats:italic>NF2<\/jats:italic> mutations. Logistic regression was used to evaluate associations with clinical variables, while transcriptomic differences were examined through differential expression and functional enrichment analyses. Immune and stromal infiltration were inferred via the xCell algorithm, cytokine signaling analyzed with Cytosig, and chemotherapeutic sensitivity predicted using the pRRophetic R package. Single-cell RNA sequencing data provided further insights into transcriptional patterns in <jats:italic>NF2<\/jats:italic>-mutated tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              <jats:italic>NF2<\/jats:italic> mutations were present in 22% of cases, with no significant correlations to histological subtype, stage, or age. <jats:italic>NF2<\/jats:italic>-mutated tumors exhibited increased infiltration of basophils, na\u00efve B cells, and pericytes, along with altered cytokine profiles, including NRG1, TGFB3, and reduced FGF2. Differentially expressed genes, such as <jats:italic>MYL7<\/jats:italic> and <jats:italic>HOXA11<\/jats:italic>, were linked to poorer survival. Chemotherapy modeling indicated higher sensitivity to camptothecin and vinblastine in <jats:italic>NF2<\/jats:italic>-mutated tumors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n              <jats:italic>NF2<\/jats:italic> mutations influence the tumor microenvironment, transcriptional landscape, and predicted therapeutic response in PM, underscoring their potential as prognostic biomarkers. These findings support tailored therapeutic strategies targeting NF2-related pathways, including Hippo signaling and cytokine modulation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00284-0","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T23:02:03Z","timestamp":1749423723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transcriptional landscape of pleural mesothelioma patients in relation to NF2 gene mutational status"],"prefix":"10.1186","volume":"37","author":[{"given":"Carlos","family":"Orozco-Casta\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mej\u00eda-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan Megan","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Carvajal-Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Bruges-Maya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Combita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Parra-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"284_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BWS Robinson","year":"2005","unstructured":"Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591\u2013603.","journal-title":"N Engl J Med"},{"key":"284_CR2","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1:491.","journal-title":"Ann Cardiothorac Surg"},{"key":"284_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316. https:\/\/doi.org\/10.1038\/ng.3520.","journal-title":"Nat Genet"},{"key":"284_CR4","doi-asserted-by":"publisher","unstructured":"Parra-Medina, R.; Casta\u00f1eda-Gonz\u00e1lez, J.P.; Chaves-Cabezas, V.; Alzate, J.P.; Chaves, J.J. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis. Pathol Res Pract. 2024;257:155276. https:\/\/doi.org\/10.1016\/j.prp.2024.155276.","DOI":"10.1016\/j.prp.2024.155276"},{"key":"284_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1101\/gad.210773.112","volume":"27","author":"F-X Yu","year":"2013","unstructured":"Yu F-X, Guan K-L. The hippo pathway: regulators and regulations. Genes Dev. 2013;27:355\u201371.","journal-title":"Genes Dev"},{"key":"284_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.molonc.2016.06.005","volume":"10","author":"M Meerang","year":"2016","unstructured":"Meerang M, B\u00e9rard K, Friess M, Bitanihirwe BKY, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG, Seifert B. Low Merlin expression and high survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma. Mol Oncol. 2016;10:1255\u201365.","journal-title":"Mol Oncol"},{"key":"284_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrd4161","volume":"13","author":"R Johnson","year":"2014","unstructured":"Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13:63\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"284_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel L, Meiller C, Assi\u00e9 J, Blum Y, Imbeaud S, Montagne F, Tranchant R, de Wolf J, Caruso S, Copin M. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14:1207\u201323.","journal-title":"Mol Oncol"},{"key":"284_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","volume":"30","author":"B Wadowski","year":"2020","unstructured":"Wadowski B, De Rienzo A, Bueno R. The molecular basis of malignant pleural mesothelioma. Thorac Surg Clin. 2020;30:383\u201393. https:\/\/doi.org\/10.1016\/j.thorsurg.2020.08.005.","journal-title":"Thorac Surg Clin"},{"key":"284_CR10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/diagnostics12123009","volume":"12","author":"J Moro","year":"2022","unstructured":"Moro J, Sobrero S, Cartia CF, Ceraolo S, Rapan\u00e0 R, Vaisitti F, Ganio S, Mellone F, Rudella S, Scopis F. Diagnostic and therapeutic challenges of malignant pleural mesothelioma. Diagnostics. 2022;12:3009.","journal-title":"Diagnostics"},{"key":"284_CR11","doi-asserted-by":"crossref","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68\u2013237ra68.","DOI":"10.1126\/scitranslmed.3008639"},{"key":"284_CR12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/cancers13071561","volume":"13","author":"H Yang","year":"2021","unstructured":"Yang H, Hall SRR, Sun B, Zhao L, Gao Y, Schmid RA, Tan ST, Peng R-W, Yao F. NF2 and canonical Hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural mesothelioma. Cancers (Basel). 2021;13:1561.","journal-title":"Cancers (Basel)"},{"key":"284_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675\u20138.","journal-title":"Nat Biotechnol"},{"key":"284_CR14","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E. J S. Signaling integrative analysis of complex cancer genomics and clinical profiles using the CBioPortal. Science signaling, 2013;6:l1.","DOI":"10.1126\/scisignal.2004088"},{"key":"284_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201323.","journal-title":"Genet Med"},{"issue":"1","key":"284_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1198\/tech.2002.s656","volume":"44","author":"H Lin","year":"2002","unstructured":"Lin H, Zelterman D. Modeling Survival Data: Extending the Cox Model. Technometrics. 2002;44(1):85\u20136. https:\/\/doi.org\/10.1198\/tech.2002.s656.","journal-title":"Technometrics"},{"key":"284_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law CW, Chen Y, Shi W, Smyth GK. Voom: precision weights unlock linear model analysis tools for RNA-Seq read counts. Genome Biol. 2014;15:1\u201317.","journal-title":"Genome Biol"},{"key":"284_CR18","doi-asserted-by":"publisher","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","volume":"49","author":"The Gene Ontology resource","year":"2021","unstructured":"The Gene Ontology resource. enriching a GOld mine. Nucleic Acids Res. 2021;49:D325\u201334.","journal-title":"Nucleic Acids Res"},{"key":"284_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. XCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. https:\/\/doi.org\/10.1186\/s13059-017-1349-1.","journal-title":"Genome Biol"},{"key":"284_CR20","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. PRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9:e107468. https:\/\/doi.org\/10.1371\/journal.pone.0107468.","journal-title":"PLoS ONE"},{"key":"284_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41592-021-01274-5","volume":"18","author":"P Jiang","year":"2021","unstructured":"Jiang P, Zhang Y, Ru B, Yang Y, Vu T, Paul R, Mirza A, Altan-Bonnet G, Liu L, Ruppin E. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat Methods. 2021;18:1181\u201391.","journal-title":"Nat Methods"},{"key":"284_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411\u201320.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"284_CR23","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","volume":"14","author":"B Giotti","year":"2024","unstructured":"Giotti B, Dolasia K, Zhao W, Cai P, Sweeney R, Merritt E, Tsankov AM. Single-cell view of tumor microenvironment gradients in pleural mesothelioma. Cancer Discovery. 2024;14(11):2262\u201378.","journal-title":"Cancer Discovery"},{"key":"284_CR24","first-page":"1","volume":"060012","author":"G Korotkevich","year":"2016","unstructured":"Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis biorxiv. 2016;060012:1\u201340.","journal-title":"Fast gene set enrichment analysis. biorxiv"},{"key":"284_CR25","doi-asserted-by":"publisher","unstructured":"Giotti B, Dolasia K, Zhao W, Cai P, Sweeney R, Merritt E, Kiner E, Kim G, Bhagwat A, Hegde S, et al. Single cell view of tumor microenvironment gradients in pleural mesothelioma. bioRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.03.14.585048.","DOI":"10.1101\/2024.03.14.585048"},{"key":"284_CR26","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/s0002-9440(10)62492-3","volume":"166","author":"GJ Gordon","year":"2005","unstructured":"Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005;166:1827\u201340. https:\/\/doi.org\/10.1016\/s0002-9440(10)62492-3.","journal-title":"Am J Pathol"},{"key":"284_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.molmed.2015.01.003","volume":"21","author":"SW Plouffe","year":"2015","unstructured":"Plouffe SW, Hong AW, Guan KL. Disease implications of the Hippo\/YAP pathway. Trends Mol Med. 2015;21:212\u201322. https:\/\/doi.org\/10.1016\/j.molmed.2015.01.003.","journal-title":"Trends Mol Med"},{"key":"284_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","volume":"163","author":"F-X Yu","year":"2015","unstructured":"Yu F-X, Zhao B, Guan K-L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811\u201328.","journal-title":"Cell"},{"key":"284_CR29","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.Cd-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0804.","journal-title":"Cancer Discov"},{"key":"284_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41419-021-03668-x","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Liang S-Q, Yang Z, Yang H, Bruggmann R, Oberhaensli S, Berezowska S, Marti TM, Hall SRR, Dorn P. Malignant pleural mesothelioma Co-Opts BCL-XL and autophagy to escape apoptosis. Cell Death Dis. 2021;12:406.","journal-title":"Cell Death Dis"},{"key":"284_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.critrevonc.2015.12.004","volume":"99","author":"M Maugeri-Sacc\u00e0","year":"2016","unstructured":"Maugeri-Sacc\u00e0 M, De Maria R. Hippo pathway and breast cancer stem cells. Crit Rev Oncol Hematol. 2016;99:115\u201322.","journal-title":"Crit Rev Oncol Hematol"},{"key":"284_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1101\/gad.1054603","volume":"17","author":"D Lallemand","year":"2003","unstructured":"Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003;17:1090\u2013100.","journal-title":"Genes Dev"},{"key":"284_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/B978-012160281-9\/50003-7","volume":"1","author":"DL Falls","year":"2003","unstructured":"Falls DL. Neuregulins: functions, forms, and signaling strategies. The EGF Receptor Family. 2003;1:15\u201331.","journal-title":"The EGF Receptor Family"},{"key":"284_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1359-6101(03)00019-4","volume":"14","author":"SR Wiley","year":"2003","unstructured":"Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR\/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241\u20139.","journal-title":"Cytokine Growth Factor Rev"},{"key":"284_CR35","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1111\/j.0959-9673.2004.00367.x","volume":"85","author":"K Flanders","year":"2004","unstructured":"Flanders K, Sato M, Ooshima A, Russo A, Roberts A. Smad-3 as a mediator of the fibrotic response. Int J Exp Pathol. 2004;85:A13\u2013A13.","journal-title":"Int J Exp Pathol"},{"key":"284_CR36","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1073\/pnas.0507367103","volume":"103","author":"RV Pusapati","year":"2006","unstructured":"Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K, McArthur MJ, Wong PK, Johnson DG. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci. 2006;103:1446\u201351.","journal-title":"Proc Natl Acad Sci"},{"key":"284_CR37","doi-asserted-by":"publisher","first-page":"E1393134","DOI":"10.1080\/2162402X.2017.1393134","volume":"7","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2018;7:E1393134.","journal-title":"Oncoimmunology"},{"key":"284_CR38","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1172\/JCI80007","volume":"125","author":"S Shalapour","year":"2015","unstructured":"Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125:3347\u201355.","journal-title":"J Clin Invest"},{"key":"284_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41698-024-00627-5","volume":"8","author":"D Xu","year":"2024","unstructured":"Xu D, Yin S, Shu Y. NF2: an underestimated player in cancer metabolic reprogramming and tumor immunity. NPJ Precis Oncol. 2024;8:133.","journal-title":"NPJ Precis Oncol"},{"key":"284_CR40","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789\u2013802.","journal-title":"Nat Rev Cancer"},{"key":"284_CR41","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A. AKT\/PKB signaling: navigating the network. Cell. 2017;169:381\u2013405.","journal-title":"Cell"},{"key":"284_CR42","doi-asserted-by":"publisher","unstructured":"Bhuvic Patel, Sangami Pugazenthi, Collin W English, Vijay Nitturi, Shree S Pari, Tatenda Mahlokozera, William A Leidig, Hsiang-Chih Lu, Alicia Yang, Kaleigh Roberts, Patrick DeSouza, Kyle P McGeehan, Diane D Mao, Namita Sinha, Joseph E Ippolito, Sonika Dahiya, Allegra Petti, Hiroko Yano, Tiemo J Klisch, Akdes S Harmanci, Akash J Patel, Albert H Kim, NF2 loss-of function and hypoxia drive radiation resistance in grade 2 meningiomas, JNCI: Journal of the National Cancer Institute, 2025:djaf022, https:\/\/doi.org\/10.1093\/jnci\/djaf022.","DOI":"10.1093\/jnci\/djaf022"},{"key":"284_CR43","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-024-06547-3","volume":"15","author":"KV Aleksandrova","year":"2024","unstructured":"Aleksandrova KV, Vorobev ML, Suvorova II. MTOR pathway occupies a central role in the emergence of latent cancer Cells. Cell Death Dis. 2024;15:176.","journal-title":"Cell Death Dis"},{"key":"284_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211\u20138.","journal-title":"Trends Biochem Sci"},{"key":"284_CR45","doi-asserted-by":"publisher","first-page":"1091779","DOI":"10.3389\/fphar.2022.1091779","volume":"13","author":"D Zhou","year":"2022","unstructured":"Zhou D, Duan Z, Li Z, Ge F, Wei R, Kong L. The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment. Front Pharmacol. 2022;13:1091779.","journal-title":"Front Pharmacol"},{"key":"284_CR46","doi-asserted-by":"crossref","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:70.","DOI":"10.1038\/s41392-023-01332-8"}],"updated-by":[{"DOI":"10.1186\/s43046-025-00310-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000}}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00284-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00284-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00284-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T14:41:28Z","timestamp":1751553688000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00284-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00284-0","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s43046-025-00310-1","asserted-by":"object"}]},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: \"the author reported that the 5th author was omitted from the author group. Carlos Carvajal-Fierro has been added to the author group and are presented correctly in this correction article.\"","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s43046-025-00310-1","URL":"https:\/\/doi.org\/10.1186\/s43046-025-00310-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}